About Trigemina, Inc.

We are committed to providing both near-term medicines that will help People experiencing neuropathic pain and the symptoms associated CNS disorders and chronic illness.

Key to our delivering on this commitment is our expertise nasal-to–brain drug delivery that facilitates the delivery of drugs across the blood brain barrier and proprietary formulas that concentrate drug in select CNS regions then enhance binding of a drug to specific receptors. Our technologies have are applicable to a broad range of candidates from the repurposing existing drugs, to delivering gene therapy to neurological tissue.

Leading our scientific team is Dave Yeomans Ph.D. who heads the Pain Research Center at Stanford University, along with Dr. Shashi Kori M.D. an internationally recognized neuroscience expert in testing of new CNS medications. Supporting our efforts is an advisory board of scientific and clinical leaders in the fields of migraine, neuroscience, oral-facial pain and gene therapy.

Helping turn science into drugs is a management team with a wealth of experience in drug delivery, CMC, intellectual property and financial management.